ExoLuminate Study for Early Detection of Pancreatic Cancer

Description

ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Conditions

Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms

Talk to us

Study Overview

On this page

Study Details

Study overview

ExoLuminate is a nationally-enrolling registry study designed for earlier detection of cancer in patients at elevated risk or clinically-suspicious for pancreatic ductal adenocarcinoma (PDAC). Those with elevated risk for PDAC can include individuals with intraductal papillary mucinous neoplasms, family history of pancreatic cancer, germline mutations in genes known to be associated with cancer, and a personal or family history of pancreatitis. The goal of the study is to compare the performance of ExoVerita™ assay in early detection of PDAC to current standard-of-care methods of surveillance.

Exoluminate Study: Observational Registry Study to Assess Exo-PDAC Assay Performance for Detection of Pancreatic Adenocarcinoma (PDAC) in High-Risk or Clinically Suspicious Patients

ExoLuminate Study for Early Detection of Pancreatic Cancer

Condition
Pancreas Cancer
Intervention / Treatment

-

Contacts and Locations

La Jolla

University of California, San Diego, La Jolla, California, United States, 92093

San Diego

Biological Dynamics, San Diego, California, United States, 92121

Santa Monica

Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States, 90404

Van Nuys

Dr. Lomis Comprehensive Surgical Center, Van Nuys, California, United States, 91405

Washington

MedStar Health Research Institute, Washington, District of Columbia, United States, 20010

Gainesville

University of Florida, Gainesville, Florida, United States, 32610

Port Orange

Bhanu Visvalingam, Port Orange, Florida, United States, 32127

Boston

Dana Farber Cancer Institute, Boston, Massachusetts, United States, 02136

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * ≥18 years old.
  • * Meeting criteria for one of the study cohorts.
  • * Capable of giving informed consent.
  • * Able to provide a blood sample.
  • * \< 18 years old.
  • * Pregnancy.
  • * Active cancer (other than pancreatic cancer) and/or undergoing treatment for an active cancer diagnosis (except for skin malignancies).
  • * Prior organ transplant or bone marrow transplant.
  • * History of fainting or other adverse effects when blood is drawn.
  • * Any condition that, in the opinion of the investigator, should preclude enrollment.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Biological Dynamics,

Harmeet Dhani, MD, M.Sc, PRINCIPAL_INVESTIGATOR, Biological Dynamics

Study Record Dates

2027-01-01